← back to search

Bruce L. Innis

Haverford College ·
Area of research
Epidemiology · Public Health, Environmental and Occupational Health
Research interest
Research interests include Mosquito-borne diseases and control, Influenza Virus Research Studies, Viral Infections and Vectors, and Hepatitis Viruses Studies and Epidemiology.
h-index
72
citations
21,573
works
262
NIH funding
primary concept
Medicine
email

Recent publications

WHO preferred product characteristics for monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease in infants – Key considerations for global use
Vaccine 2022cited by 38position: middledoi
A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial
Nature Medicine 2020cited by 355position: middledoi
Does respiratory syncytial virus lower respiratory illness in early life cause recurrent wheeze of early childhood and asthma? Critical review of the evidence and guidance for future studies from a World Health Organization-sponsored meeting
Vaccine 2020cited by 104position: middledoi
Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial
The Lancet Infectious Diseases 2019cited by 140position: middledoi
Clinical development and regulatory points for consideration for second-generation live attenuated dengue vaccines
Vaccine 2018cited by 75position: middledoi
Corrigendum to “One or two doses of live varicella virus-containing vaccines: Efficacy, persistence of immune responses, and safety six years after administration in healthy children during their second year of life” [Vaccine 36 (2018) 381–387]
Vaccine 2018cited by 1position: lastdoi
One or two doses of live varicella virus-containing vaccines: Efficacy, persistence of immune responses, and safety six years after administration in healthy children during their second year of life
Vaccine 2017cited by 26position: lastdoi
AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial
The Lancet Infectious Diseases 2013cited by 164position: middledoi
Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years
BMC Infectious Diseases 2013cited by 104position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Peter G. Smith · Kenya Medical Research Institute3 papers (2018–2022)Deshayne B. Fell · University of Ottawa2 papers (2020–2022)Heather J. Zar · Medical Research Council2 papers (2020–2022)Daniel R. Feikin · Centers for Disease Control and Prevention2 papers (2020–2022) · 2 papers (2017–2018) · 2 papers (2017–2018)Giovanni Gabutti · University of Ferrara2 papers (2017–2018)Jerzy Brzostek · University of Dundee2 papers (2017–2018)Fred Were · University of Cape Town2 papers (2020–2022) · 2 papers (2017–2018) · 2 papers (2017–2018) · 2 papers (2017–2018) · 2 papers (2017–2018)Ruth A. Karron · Johns Hopkins University2 papers (2020–2022) · 2 papers (2017–2018) · 2 papers (2017–2018) · 2 papers (2020–2022) · 2 papers (2017–2018) · 2 papers (2017–2018)Harish Nair · University of Edinburgh2 papers (2020–2022)